• Explore /
  • Poster
  • / Anlotinib plus TQB2450 as adjuvant therapy in patients with esophageal squamous cell carcinoma: A phase II study (ALTER-E005).

Anlotinib plus TQB2450 as adjuvant therapy in patients with esophageal squamous cell carcinoma: A phase II study (ALTER-E005).

Abstract Poster

Authors

null

Changying Guo

Jiangxi Provincial Tumor Hospital, Nanchang, China

Changying Guo , Shengjia Chen , Yongqiang Ye , Xiao-Bing Li , Weimin Mao

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT05252078

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr 347)

DOI

10.1200/JCO.2024.42.3_suppl.347

Abstract #

347

Poster Bd #

G8

Abstract Disclosures

Similar Posters

First Author: Changying Guo

First Author: Xianhai Mao

First Author: Hui Zeng

First Author: Jie Liu